is saving up for the escape
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
https://finance.yahoo.com/quote/SYA.AX?p=SYA.AX in case you want to keep in touch with the price while US is on holiday.
$VHC Bought a ton of $10 calls in case it gets some squeezy action. That's some great news.
https://www.reuters.com/article/us-apple-virnetx/apple-fails-to-overturn-virnetx-patent-verdict-could-owe-over-11-billion-idUSKBN29K2DU
In a decision issued on Friday, U.S. District Judge Robert Schroeder in Tyler, Texas rejected Apple’s request for a new trial and several other claims.
These included that VirnetX’s award should not exceed $113.7 million, and that jurors should have been told the U.S. Patent and Trademark Office had deemed VirnetX’s claims “unpatentable.”
Jurors in October found that Apple infringed two VirnetX patents related to secure networks, known as virtual private networks, to which owners of various iPhones and iPads may connect.
Schroeder also awarded royalties of 84 cents per unit for future infringements, mirroring the rate set by the jury. Apple had said future royalties should be zero, or else no more than 19 cents per unit.
Apple and VirnetX did not immediately respond to requests for comment.
In afternoon trading, VirnetX shares were up 54 cents, or 10.8%, at $5.63.
Apple, based in Cupertino, California, and VirnetX, based in Zephyr Cove, Nevada, have battled in patent litigation for more than a decade.
Last March, Apple paid VirnetX $454 million after the U.S. Supreme Court refused to hear the iPhone maker’s appeal in an earlier patent case.
In a Dec. 18 court filing, Apple said the latest award could boost its payout in both cases to $1.116 billion.
The case is VirnetX Inc v. Apple Inc, U.S. District Court, Eastern District of Texas, No. 12-00855.
$DMNXF .0395 basically a subsidiary of $PLL $40.54 now...
LOL Cramer blocked me a while back for something, or I would alert him myself :)
Lots of shorts I reckon...they always hold it down for a while. Should see $10+ a/h I hope.
$VHC huge verdict...might squeeze here.
https://stocktwits.com/TradeSquawk/message/273986816
Ask getting cleared $DMNXF
$NTRR fresh hemp play going:
Katy, TX , Jan. 14, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neutra Corporation’s (OTC PINK:NTRR) new national sales team reports it has received solid interest in VIVIS’ transdermal CBD products from multiple well-known nationwide and regional retail chains.
“Large retailers are seeing the success smaller outfits are having with hemp-based CBD,” said Neutra CEO Sydney Jim . “Now they want a piece of that action. VIVIS can give them that opening. The chains had a positive impression of our brand and the transdermal samples we provided. The stores particularly appreciated VIVIS’ insistence on testing and quality, which, of course, is our primary market differentiator. We’re optimistic about future co-operation and sales opportunities.”
Unlike CBD derived from cannabis, hemp-based CBD, such as that used by VIVIS, does not produce a high. This makes it legal for use in many states that outlaw cannabis. Large retail chains can stock and sell hemp-based CBD products, like transdermal creams and ointments, without worry about potential legal implications. And the fact that VIVIS lab tests each batch of product to assure potency, purity and quality should be appealing to major chains and their customers, especially those customers hesitant to enter a CBD store.
Demand for hemp-based CBD products continues its upward trend. According to market research group Brightfield, 40 percent of existing CBD users said they have increased their consumption in recent months. Prices from premium products have fallen, making quality offerings, such as those sold by VIVIS, more affordable for a greater number of buyers. Having its products stocked at major retail chains could bring in new customers who have never tried a hemp-based CBD product and greatly expand VIVIS’ market share.
To learn more about VIVIS hemp-based CBD products, visit the company's website at https://viviscorp.com. ; After the migration of our new website, our site will return to http://viviscbd.com.
$NTRR .0028 fresh hemp play, had news yesterday:
Katy, TX , Jan. 14, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neutra Corporation’s (OTC PINK:NTRR) new national sales team reports it has received solid interest in VIVIS’ transdermal CBD products from multiple well-known nationwide and regional retail chains.
“Large retailers are seeing the success smaller outfits are having with hemp-based CBD,” said Neutra CEO Sydney Jim . “Now they want a piece of that action. VIVIS can give them that opening. The chains had a positive impression of our brand and the transdermal samples we provided. The stores particularly appreciated VIVIS’ insistence on testing and quality, which, of course, is our primary market differentiator. We’re optimistic about future co-operation and sales opportunities.”
Unlike CBD derived from cannabis, hemp-based CBD, such as that used by VIVIS, does not produce a high. This makes it legal for use in many states that outlaw cannabis. Large retail chains can stock and sell hemp-based CBD products, like transdermal creams and ointments, without worry about potential legal implications. And the fact that VIVIS lab tests each batch of product to assure potency, purity and quality should be appealing to major chains and their customers, especially those customers hesitant to enter a CBD store.
Demand for hemp-based CBD products continues its upward trend. According to market research group Brightfield, 40 percent of existing CBD users said they have increased their consumption in recent months. Prices from premium products have fallen, making quality offerings, such as those sold by VIVIS, more affordable for a greater number of buyers. Having its products stocked at major retail chains could bring in new customers who have never tried a hemp-based CBD product and greatly expand VIVIS’ market share.
To learn more about VIVIS hemp-based CBD products, visit the company's website at https://viviscorp.com. ; After the migration of our new website, our site will return to http://viviscbd.com.
$DMNXF .0369 market finding this finally...
$DMNXF Market finding this...will be HUGE IMO.
1/11/21 NEW YORK --(BUSINESS WIRE)-- Piedmont Lithium Limited (“ Piedmont ” or “Company”) is pleased to announce that it has entered into agreements (“Agreements”) to establish a strategic partnership with Sayona Mining Limited (“Sayona”) (ASX:SYA) through the purchase of equity stakes in Sayona and its 100% owned Quebec subsidiary, Sayona Quebec Inc (“Sayona Quebec”), as well as a binding supply agreement for at least 50% of Sayona Quebec’s planned spodumene concentrate production.
Piedmont will acquire an initial 9.9% equity interest in Sayona for approximately US$3.1 million (“Share Placement”) and two unsecured convertible notes (“Convertible Notes”) for approximately US$3.9 million that upon conversion would result in Piedmont acquiring an additional 10.0% equity interest in Sayona. Piedmont will appoint one director to Sayona’s Board of Directors. Piedmont will also purchase a 25.0% stake in Sayona Quebec for approximately US$5.0 million in cash (“ Project Investment ”). Sayona Quebec owns the DFS-level Authier lithium project, the highly prospective Tansim lithium project, and is pursuing a bid to acquire Quebec -based North American Lithium’s (“NAL”) assets.
Piedmont and Sayona Quebec have also entered into a binding spodumene concentrate (“SC6”) supply agreement (“Supply Agreement”) pursuant to which Sayona Quebec will supply to Piedmont the greater of 60,000 t/y or 50% of Sayona Quebec’s SC6 production at market prices on a life-of-mine basis.
The Share Placement and issue of the Convertible Notes are expected to close the week of January 11, 2021 with the Project Investment expected to close in February 2021 . Material terms of the Agreements are included in the Summary of Transaction Terms at the end of this announcement.
Keith D. Phillips , President and Chief Executive Officer, commented: “Piedmont’s partnership with Sayona will provide multiple benefits. Sayona has high quality asset in a favorable location, and the investments are being made at an attractive valuation. The investments are additive to Piedmont from a resources and reserves perspective, and the spodumene supply agreement will offset our Tesla commitments in the near term and position us for longer term growth in lithium hydroxide production. Furthermore, Sayona’s pursuit of the brownfield assets of NAL offers a unique regional consolidation opportunity.
“Quebec is poised to become an important lithium hydroxide production center given its abundant mineral resources, low-cost, sustainable hydro-electric power, proximity to major US and European electric vehicle markets, and pro-electrification stance of provincial leaders. Sayona’s assets are favorably located in the Val-d’Or region of central Quebec , home to major mining concerns and proximate to first-class infrastructure. Sayona’s core Authier project is well-advanced, with reserves declared and DFS complete, the nearby Tansim project offers strong exploration potential, and the regional consolidation opportunities including NAL are intriguing.”
“This is a very exciting step for Piedmont . We look forward to supporting Sayona’s team as they drive day-to-day activities in Quebec , while Piedmont’s team focuses on its core interests in North Carolina . 2021 will be an important year for our Piedmont Lithium Project , as we plan to expand our mineral resources, finalize permitting, execute additional lithium offtake agreements, complete an integrated definitive feasibility study, and secure strategic project financing. We are fortunate to have a strong balance sheet to comfortably fund the Sayona investments without compromising our aggressive plans in North Carolina.”
$AVGR $1.85 billion dollar news IMO:
REDWOOD CITY, CA / ACCESSWIRE / January 15, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced full commercial launch of its Tigereye™ image-guided chronic total occlusion (CTO) crossing system. With the initiation of full commercial launch, current and prospective accounts throughout the US and Germany are now able to order the Tigereye device.
During the fourth quarter of 2020, Avinger conducted a limited launch at 12 clinical centers in the U.S. and Germany . Approximately 50 CTO cases were successfully performed, showcasing Tigereye's advanced clinical capabilities and excellent product reliability in a variety of lesion types and settings.
"The limited launch program demonstrated Tigereye's strong clinical results and efficiency across a wide range of PAD cases," commented Dr. Jaafer Golzar , an interventional cardiologist and Avinger's Chief Medical Officer. "The enhanced imaging, higher rotational speeds and ability to precisely control the device inside the vessel are truly remarkable advancements in Avinger's family of intravascular OCT-guided catheters. Physicians have been able to consistently, safely and effectively cross complex CTOs, including cases that may have required more invasive procedures such as bypass or amputation, fully demonstrating the unique benefits of Avinger's proprietary image-guided technology."
Jeff Soinski , Avinger's President and CEO, said, "We are excited to progress to full commercial launch of our next-generation Tigereye device. The limited launch program conducted with 14 physician users affirmed our belief that Tigereye represents an important advance for physicians seeking better solutions on behalf of their CTO patients, who often present with the most challenging and complex PAD cases.
"We believe full commercial availability of the Tigereye device will be an important contributor to expanding our revenue growth opportunities in 2021, both in terms of attracting new Avinger user sites and supporting higher utilization per site," Soinski continued. "With three new product families launched in less than three years, Avinger offers physicians a comprehensive suite of the most advanced PAD therapeutic devices available today to provide effective, measurable treatment options with superior patient outcomes."
Tigereye features high definition, real-time intravascular imaging and a user-controlled deflectable tip designed for steerability within the lumen. Tigereye also includes an enhanced distal tip configuration with rotational speeds up to 1000 RPM designed to penetrate challenging lesions. The Tigereye catheter has a working length of 140 cm and 5 French sheath compatibility to enable treatment of lesions in peripheral vessels both above and below the knee. Tigereye is complementary to Avinger's image-guided atherectomy line of catheters, including the Pantheris Next Generation and Pantheris SV devices.
Avinger's proprietary Lumivascular technology allows physicians, for the first time ever, to see from inside the artery during an atherectomy or CTO crossing procedure by using an imaging modality called optical coherence tomography, or OCT, that is displayed on Avinger's Lightbox console. Physicians performing atherectomy or crossing CTOs with other devices must rely solely on X-ray and tactile feedback to guide their interventions while treating complicated arterial disease. With the Lumivascular approach, physicians can more accurately navigate their devices and treat PAD lesions, thanks to the real-time OCT images generated from inside the artery, without exposing healthcare workers and patients to the negative effects of ionizing radiation.
$TLRY nutso move...
$EVIO radar on this:
$EVIO CEO email today confirms Merger!!
— BROWN BULL (@flyhigh_ca) January 14, 2021
It says “They received approval from California BCC to operate a new lab, merged with Steep Hill, at the new location in Berkeley”
New labs.. Double Revenues!!
1 year high is .08!
Sleeping Giant at .005
The run not yet started!! 🔥🤫🤩 pic.twitter.com/RtxDG71mqy
$EVIO HUGE:
$EVIO CEO email today confirms Merger!!
— BROWN BULL (@flyhigh_ca) January 14, 2021
It says “They received approval from California BCC to operate a new lab, merged with Steep Hill, at the new location in Berkeley”
New labs.. Double Revenues!!
1 year high is .08!
Sleeping Giant at .005
The run not yet started!! 🔥🤫🤩 pic.twitter.com/RtxDG71mqy
$FST $FST/WS going a bit a/h.
Agree, g/l!
In FST/WS Fertitta deal.
https://seekingalpha.com/news/3651586-fast-acquisition-spac-gains-on-reported-deal-tilman-fertitta
Looks decent...hopefully they go for Lithium.
$GME sold my $30's will load up farther out.
Loaded some here. Sleeper.
$GME moving up a/h...
Maybe Cramer does a mention on his show??
$VDRM .026
$VDRM .0148 hits...
$VDRM hit .0127, next leg coming.
Authorized Shares
1,000,000,000
12/16/2020
Outstanding Shares
787,564,784
12/16/2020
Restricted
98,456,186
12/16/2020
Unrestricted
689,108,598
12/16/2020
Held at DTC
666,758,161
12/16/2020
Float
620,848,535
03/31/2019
$GME chart cooled a bit...$40+ cometh...
$VDRM .0094 float has almost traded now...
$VDRM .009 float has almost traded...might see a few cents.
$GME nearly got shook on the dipsky...